Crohn's disease clinical trials near Vancouver
17 recruiting trials in the official registry · updated July 2026 · free · no account · no tracking · English & français
Searches within 160 km deliberately include sites across the US border — often a Canadian patient's nearest option.
Search near your location →Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Recruiting nowPhase 385 sites
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness,…
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Recruiting nowPhase 381 sites
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab…
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Recruiting nowPhase 385 sites
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in …
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
Recruiting now25 sites
The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well a…
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Recruiting nowPhase 3499 sites
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to …
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Recruiting nowPhase 3301 sites
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD.…
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Recruiting nowPhase 2190 sites
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severel…
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Recruiting nowPhase 396 sites
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to c…
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Recruiting nowPhase 322 sites
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[wo…
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Recruiting nowPhase 3102 sites
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract…
Common questions
How do I find a crohn's disease clinical trial near me in Canada?
Use Beacon's free search: enter "crohn's disease", your age, and your location, and you'll see recruiting trials sorted by distance, each explained in plain language — including sites just across the US border. Beacon searches the full official registry and never requires an account.
Does joining a clinical trial cost money?
The study treatment and study-related tests are usually provided at no cost, and some trials help with travel. In Canada, your provincial health coverage continues to apply to your routine care — always confirm details with the study team.
Can I leave a clinical trial after joining?
Yes. Participation is always voluntary, and you can leave a trial at any time, for any reason, without losing your normal medical care.
Do I qualify for these trials?
Every trial has its own eligibility criteria. Beacon translates each trial's criteria into a plain-language checklist you can review and bring to your doctor — only the study team can confirm whether you qualify.
Page updated July 2026.